News
-
-
COMMUNIQUÉ DE PRESSE
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
Defence Therapeutics Inc. announces successful testing of second-generation cancer vaccine ARM-002TM, utilizing AccuTOX® molecule for tumor eradication. Promising results in melanoma model point to potential breakthrough in cancer treatment -
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
Defence Therapeutics announces successful results for second-generation anti-cancer vaccine ARM-002TM, showing promising anti-tumoral response in melanoma model and plans for Phase I trial targeting solid tumors -
-
-
-
-